Medication in autism spectrum disorder

Author/s
Paramala Santosh
Citation
Issue 4 Summer 2014
CEPiP.2014.1.143-155
Abstract

Medication can reduce the impact of interfering symptoms, improving the lives of individuals with autism spectrum disorder (ASD) and their families. Although there are no widely-accepted medications for treating the core symptoms of ASD, clinical trials have provided evidence for efficacy and tolerability of medication used for treating comorbid psychiatric conditions. A number of these have a good evidence base, including stimulant medication for the features of attention deficit hyperactivity disorder and risperidone for improving behaviour. Treatment with psychopharmacological agents should only be undertaken after a careful assessment to ensure that any psychiatric symptoms are not the result of underlying physical disorders and to determine which symptoms should be targeted. The aim is to choose and adjust medication that achieves maximum benefit with minimum adverse effects.

Cite as: Cutting Edge Psychiatry in Practice 2014, 4(1):143-155; https://doi.org/10.65031/hdeb8212

References

  1. Belmonte MK, Allen G, Beckel-Mitchener A, Boulanger LM, Carper RA, Webb SJ. Autism and abnormal development of brain connectivity. J Neurosci 2004 Oct 20;24(42):9228-31. https://doi.org/10.1523/jneurosci.3340-04.2004
  2. Hadjikhani N, Joseph RM, Snyder J, Chabris CF, Clark J, Steele S, et al. Activation of the fusiform gyrus when individuals with autism spectrum disorder view faces. Neuroimage 2004 Jul;22(3):1141-50. https://doi.org/10.1016/j.neuroimage.2004.03.025
  3. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005 Jun;162(6):1142-8. https://doi.org/10.1176/appi.ajp.162.6.1142
  4. Doyle-Thomas KA, Card D, Soorya LV, Wang AT, Fan J, Anagnostou E. Metabolic mapping of deep brain structures and associations with symptomatology in autism spectrum disorders. Res Autism Spectr Disord 2014 Jan;8(1):44-51. https://doi.org/10.1016/j.rasd.2013.10.003
  5. Santosh PJ, Baird G. Psychopharmacotherapy in children and adults with intellectual disability. Lancet 1999 Jul 17;354(9174):233-42. https://doi.org/10.1016/s0140-6736(98)07059-7
  6. Hamrin V, McCarthy EM, Tyson V. Pediatric psychotropic medication initiation and adherence: a literature review based on social exchange theory. J Child Adolesc Psychiatr Nurs 2010 Aug;23(3):151-72. https://doi.org/10.1111/j.1744-6171.2010.00237.x
  7. Santosh PJ. STOP study aims to monitor suicidality. EU Research Volume 2014;(1):36-9.   
  8. Santosh PJ. Medication for children and adolescents - current issues. In: Gelder M, Andreasen N, Lopez-Ibor JJ, Geddes J, editors. New Oxford Textbook of Psychiatry. First ed. Oxford: Oxford University Press; 2009. p. 1793-9. https://doi.org/10.1093/med/9780199696758.001.0001
  9. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004;14(3):455-63. https://doi.org/10.1089/cap.2004.14.455
  10. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009 Dec;124(6):1533-40. https://doi.org/10.1542/peds.2008-3782
  11. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009 Nov;48(11):1110-9. https://doi.org/10.1097/chi.0b013e3181b76658
  12. Findling RL, Mankoski R, Timko K, Lears K, McCartney T, McQuade RD, et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry 2014 Jan;75(1):22-30. https://doi.org/10.4088/jcp.13m08500
  13. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002 Aug 1;347(5):314-21.               
  14. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry 2005 Jun;162(6):1142-8. https://doi.org/10.1176/appi.ajp.162.6.1142
  15. Troost PW, Lahuis BE, Steenhuis MP, Ketelaars CE, Buitelaar JK, van EH, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005 Nov;44(11):1137-44. https://doi.org/10.1097/01.chi.0000177055.11229.76
  16. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004 Nov;114(5):e634-e641. https://doi.org/10.1542/peds.2003-0264-f
  17. Posey DJ, Stigler KA, Erickson CA, McDougle CJ. Antipsychotics in the treatment of autism. J Clin Invest 2008 Jan;118(1):6-14. https://doi.org/10.1172/jci32483
  18. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006 Jun;21(6):450-5. https://doi.org/10.1177/08830738060210060801
  19. Akhondzadeh S, Fallah J, Mohammadi MR, Imani R, Mohammadi M, Salehi B, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 2010 Feb 1;34(1):32-6. https://doi.org/10.1016/j.pnpbp.2009.09.012
  20. Gupta S. Immunological treatments for autism. J Autism Dev Disord 2000 Oct;30(5):475-9. https://doi.org/10.1023/a:1005568027292
  21. Gupta S, Rimland B, Shilling PD. Pentoxifylline: brief review and rationale for its possible use in the treatment of autism. J Child Neurol 1996 Nov;11(6):501-4. https://doi.org/10.1177/088307389601100622
  22. Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006 Oct;16(5):541-8. https://doi.org/10.1089/cap.2006.16.541
  23. Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol 2011 Nov;34(6):216-9. https://doi.org/10.1097/wnf.0b013e31823349ac
  24. Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 2005 Jun;35(3):387-91. https://doi.org/10.1007/s10803-005-3306-1
  25. Cohen SA, Fitzgerald BJ, Khan SR, Khan A. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 2004 Jan;65(1):110-3. https://doi.org/10.4088/jcp.v65n0119
  26. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry 1996 May;153(5):738.       
  27. Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. J Psychiatry Neurosci 2001 Sep;26(4):340-1.      
  28. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984 Oct;141(10):1195-202. https://doi.org/10.1176/ajp.141.10.1195
  29. Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 2006 Sep;32(5):575-83. https://doi.org/10.1111/j.1365-2214.2006.00631.x
  30. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005 Nov;62(11):1266-74. https://doi.org/10.1001/archpsyc.62.11.1266
  31. Simonoff E, Taylor E, Baird G, Bernard S, Chadwick O, Liang H, et al. Randomized controlled double- blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. J Child Psychol Psychiatry 2013 May;54(5):527-35. https://doi.org/10.1111/j.1469-7610.2012.02569.x
  32. Campbell M, Fish B, David R, Shapiro T, Collins P, Koh C. Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Child Schizophr 1972 Oct;2(4):343-58. https://doi.org/10.1007/bf01538168
  33. Campbell M, Small AM, Collins PJ, Friedman E, David R, Genieser N. Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Curr Ther Res Clin Exp 1976 Jan;19(1):70-86.     
  34. Jou RJ, Handen BL, Hardan AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005 Apr;15(2):325-30. https://doi.org/10.1089/cap.2005.15.325
  35. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006 Oct;16(5):599-610. https://doi.org/10.1089/cap.2006.16.599
  36. Troost PW, Steenhuis MP, Tuynman-Qua HG, Kalverdijk LJ, Buitelaar JK, Minderaa RB, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 2006 Oct;16(5):611-9. https://doi.org/10.1089/cap.2006.16.611
  37. Harfterkamp M, Loo-Neus G, Minderaa RB, van der Gaag RJ, Escobar R, Schacht A, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2012 Jul;51(7):733-41. https://doi.org/10.1016/j.jaac.2012.04.011
  38. Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 2008;16(2):97-112. https://doi.org/10.1080/10673220802075852
  39. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo- controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992 Mar;53(3):77-82.               
  40. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004;14(2):233-41. https://doi.org/10.1089/1044546041649084
  41. Scahill L, Aman MG, McDougle CJ, McCracken JT, Tierney E, Dziura J, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006 Oct;16(5):589-98. https://doi.org/10.1089/cap.2006.16.589
  42. Scahill L, Hallett V, Aman MG, McDougle CJ, Eugene AL, McCracken JT, et al. Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord 2013 Mar;43(3):739-46. https://doi.org/10.1007/s10803-012-1689-3
  43. Malone RP, Gratz SS, Delaney MA, Hyman SB. Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders. CNS Drugs 2005;19(11): 923-34. https://doi.org/10.2165/00023210-200519110-00003
  44. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005 Mar;30(3):582-9. https://doi.org/10.1038/sj.npp.1300627
  45. Couturier JL, Nicolson R. A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2002;12(3):243-8. https://doi.org/10.1089/104454602760386932
  46. Namerow L, Thomas P, Bostic JQ, Prince J, Monuteaux MC. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 2003 Apr;24(2):104-8. https://doi.org/10.1097/00004703-200304000-00005
  47. Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2013;8:CD004677. https://doi.org/10.1002/14651858.cd004677.pub3
  48. van Steensel FJ, Bogels SM, Perrin S. Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis. Clin Child Fam Psychol Rev 2011 Sep;14(3):302-17. https://doi.org/10.1007/s10567-011-0097-0
  49. Narayanan A, White CA, Saklayen S, Scaduto MJ, Carpenter AL, Abduljalil A, et al. Effect of propranolol on functional connectivity in autism spectrum disorder--a pilot study. Brain Imaging Behav 2010 Jun;4(2):189-97. https://doi.org/10.1007/s11682-010-9098-8
  50. Cortesi F, Giannotti F, Ivanenko A, Johnson K. Sleep in children with autistic spectrum disorder. Sleep Med 2010 Aug;11(7):659-64. https://doi.org/10.1016/j.sleep.2010.01.010
  51. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006 Sep;32(5):585-9. https://doi.org/10.1111/j.1365-2214.2006.00616.x
  52. Gringras P, Gamble C, Jones AP, Wiggs L, Williamson PR, Sutcliffe A, et al. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ: British Medical Journal 2011;345:e6664. https://doi.org/10.1136/bmj.e6664
  53. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001 Jul;62(7):530-4. https://doi.org/10.4088/jcp.v62n07a05
  54. Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese RM, et al. A double-blind, placebo- controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005 Aug;15(4):682-92. https://doi.org/10.1089/cap.2005.15.682
  55. Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010 Mar;35(4):990-8. https://doi.org/10.1038/npp.2009.202
  56. Kerbeshian J, Burd L, Fisher W. Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. J Clin Psychopharmacol 1987 Dec;7(6):401-5. https://doi.org/10.1097/00004714-198712000-00005
  57. Krieger FV, Pheula GF, Coelho R, Zeni T, Tramontina S, Zeni CP, et al. An open-label trial of risperidone in children and adolescents with severe mood dysregulation. J Child Adolesc Psychopharmacol 2011 Jun;21(3):237-43. https://doi.org/10.1089/cap.2010.0123
  58. Elchaar GM, Maisch NM, Augusto LM, Wehring HJ. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother 2006 Jun;40(6):1086-95. https://doi.org/10.1345/aph.1g499
  59. Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, van EH. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo- controlled studies. Arch Gen Psychiatry 1995 Sep;52(9):766-73. https://doi.org/10.1001/archpsyc.1995.03950210060011
  60. Akhondzadeh S, Tajdar H, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Shabstari OL, et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev 2008 Sep;39(3):237-45. https://doi.org/10.1007/s10578-007-0084-3
  61. Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010 Apr 1;67(7):692-4. https://doi.org/10.1016/j.biopsych.2009.09.020
  62. Erickson CA, Mullett JE, McDougle CJ. Brief report: acamprosate in fragile X syndrome. J Autism Dev Disord 2010 Nov;40(11):1412-6. https://doi.org/10.1007/s10803-010-0988-9
  63. Khwaja OS, Ho E, Barnes KV, O’Leary HM, Pereira LM, Finkelstein Y, et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A 2014 Mar 25;111(12):4596-601. https://doi.org/10.1073/pnas.1311141111
  64. Roke Y, Buitelaar JK, Boot AM, Tenback D, van Harten PN. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. J Child Adolesc Psychopharmacol 2012 Dec;22(6):432-9. https://doi.org/10.1089/cap.2011.0109
  65. Stigler KA, Potenza MN, Posey DJ, McDougle CJ. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr Drugs 2004;6(1):33-44. https://doi.org/10.2165/00148581-200406010-00003